Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Oct 16, 2026 · Filed Oct 19, 2026
X4 Pharmaceuticals's Executive Chairman paid $12K out of pocket for X4 Pharmaceuticals shares. It was the first purchase in 12 months.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market purchase
Code P — open-market or private purchase
~$11,884
Shares × reported transaction price
<$25K
+1.4%
Purchase shares ÷ estimated pre-transaction holdings, from the filing
First purchase in 12 months
Confirmed open-market purchases by the same insider in the available history
No
Compared with 1 earlier confirmed purchase
No other insider purchases within 30 days
Distinct insiders at the same issuer with confirmed open-market purchases
Closed at $2.59 on Oct 16, 2026, 6% above its 52-week low and 45% below its high, after a 36% drop over the previous 30 trading days
52-week range $2.45 (Oct 14, 2026) to $4.67 (Jun 30, 2026), 6% of the way up, from 251 adjusted closes. 30 trading days earlier: $4.04 on Sep 3, 2026. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | +7.6% | +0.1% | +7.5% |
Past results only. Not a forecast.
Fund moves
The holder reported owning less than 5%, which ends its duty to keep reporting this stake.
David Kirske (Chief Financial Officer) sold ~$34K of X4 Pharmaceuticals
Automatic saleJohn Volpone (President) sold ~$109K of X4 Pharmaceuticals
Automatic saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
